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Abstract
Background:  The association of Chlamydia pneumoniae with atherosclerosis is controversial. We
investigated the presence of C. pneumoniae and other Chlamydia spp. in atheromatous carotid artery
tissue.
Methods:  Forty elective carotid endarterectomy patients were recruited (27 males, mean age 65
and 13 females mean age 68), 4 had bilateral carotid endarterectomies (n= 44 endarterectomy
specimens). Control specimens were taken from macroscopically normal carotid artery adjacent
to the atheromatous lesions (internal controls), except in 8 cases where normal carotid arteries
from post mortem (external controls) were used. Three case-control pairs were excluded when
the HLA DRB gene failed to amplify from the DNA. Genus specific primers to the major outer
membrane protein (MOMP) gene were used in a nested polymerase chain reaction (nPCR) in 41
atheromatous carotid specimens and paired controls. PCR inhibition was monitored by spiking
with target C. trachomatis. Atheroma severity was graded histologically. Plasma samples were tested
by microimmunofluorescence (MIF) for antibodies to C. pneumoniae, C. trachomatis and C. psittaci
and the corresponding white cells were tested for Chlamydia spp. by nPCR.
Results:   C. pneumoniae was not detected in any carotid specimen. Twenty-five of 38 (66%) plasma
specimens were positive for C. pneumoniae IgG, 2/38 (5%) for C. trachomatis IgG and 1/38 (3%) for
C. psittaci IgG.
Conclusions:  We were unable to show an association between the presence of Chlamydia spp.
and atheroma in carotid arteries in the presence of a high seroprevalence of C. pneumoniae
antibodies in Northern Ireland.
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Background
C. pneumoniae is a respiratory pathogen causing com-
munity-acquired pneumonia, bronchitis, pharyngitis
and sinusitis [1]. While an association between C. pneu-
moniae and atherosclerosis has been suggested, its exact
role in the pathogenesis of atherosclerosis remains un-
certain. Some, but not all, seroepidemiological studies
[2],[3] have shown elevated antibody levels to C. pneu-
moniae in patients with coronary artery disease and
many studies have also detected the presence of C. pneu-
moniae in atherosclerotic tissue [4],[5].However, others
have either failed to detect the organism [6] or demon-
strated a low prevalence in arterial tissues [7].
The fact that both C. psittaci and C. pneumoniae are res-
piratory pathogens and that the pathogenesis of C. pneu-
moniae and atherosclerosis may be analogous to the
development of trachoma by C. trachomatis[8], would
support the necessity to determine whether other
Chlamydia spp. beside C. pneumoniae are present in ar-
terial tissue. In this study we aimed to investigate the
presence of Chlamydia spp. in carotid artery atheroma
using genus specific chlamydia primers in a nested
polymerase chain reaction (nPCR).
Materials and Methods
Patients and specimens
Specimens were collected from 40 patients enrolled for
elective carotid endarterectomy between 1998 and 1999.
Patients' ages ranged from 42 to 84 years and included
27 males (mean age 65) and 13 females (mean age 68).
Four patients (2 males and 2 females) had bilateral ca-
rotid endarterectomies giving a total of 44 endarterecto-
my specimens. All specimens were graded
macroscopically as follows: Grade 0 normal artery,
Grade 1 fatty streak, Grade 2 fibrolipid plaque and Grade
3 advanced lesion with fibrosis, calcification, ulceration
or haemorrhage [9].
For each specimen macroscopically normal artery adja-
cent to the atheromatous area, removed as part of the
normal surgical procedure, was used as an internal con-
trol (36 specimens). Endarterectomy specimens which
did not have macroscopically normal areas adjacent to
the atheromatous section were age and sex matched with
external controls taken from normal post-mortem carot-
id arteries (8 specimens) following consent from rela-
tives of the deceased. The carotid arteries were collected
immediately from theatre and divided into two main sec-
tions, atheromatous and non-atheromatous, using a
sterile technique. Each section was further divided to ob-
tain specimens for histology, which were stored in 10%
non-buffered formalin. Specimens not processed for his-
tology were transferred to polypropylene tubes (Sarstedt
Ltd., Leicester, England), snap-frozen in liquid nitrogen,
and stored at -70°C until processed. A 5 ml blood sample
was taken into ethylenediamine tetraacetic acid (EDTA)
from each patient on admission.
Polymerase chain reaction (PCR)
Specimen processing
Preparation of carotid arteries DNA was extracted from
25–30 mg of the carotid tissue from each patient using
the QIAamp Tissue Kit (Qiagen Ltd., Crawley, Eng-
land).The extract was stored at -70°C until tested.
Preparation of White Cells And Plasma. Whole blood in
EDTA was spun in a plastic conical centrifuge tube
(Nunc, Kamstrup, Denmark) at 330 g for 5 minutes and
the plasma removed to a 1.8 ml polypropylene tube
(Sarstedt Ltd., Leicester, England). The cell pellet was
made up to 10 ml with red cell lysing buffer containing
0.15 M NH4CL, 0.01 M NaHCO3 and 1 mM EDTA (Sig-
ma, Poole, England), left at room temperature for 15
minutes and spun at 330 g for 5 minutes. The superna-
tant was replaced with 10 ml of PBS and the tube invert-
ed gently 4 times. After a second spin at 330 g for 5
minutes the supernatant was removed and the cells
counted in a Kova Glasstic 10 well grid (Hycor Biomedi-
cal Inc., California, USA) before making up to a final con-
centration of 1 ×  107 cells/ml in white cell lysing buffer
constituted from 4 M guanidinium isothiocyanate in 3 M
sodium acetate (Sigma, Poole, England) at pH 6.0. A vol-
ume of 200 µ l (equivalent to 2 – 106 cells) was extracted
using the QIAamp Blood Kit ((Qiagen Ltd., Crawley,
England). White cells and plasma were stored at -70°C
until tested.
Primers
The primers used are shown together with the size of
their respective 1st and 2nd round products (Table 1).
Mastermixes for PCR
The final 25 µl volume of the the 1st round reaction mix
for Chlamydia spp. nPCR contained 5 pmol and 25 pmol
of the outer primers CHL2A and CHL2B respectively, 10
mM Tris-HCl pH 9.0, 3.5 mM MgCl2, 50 mM KCl, 0.2
mM for each dNTP, 0.1% Triton X-100 and 0.625 units
of Taq enzyme. The final 25 µl volume for HLADRB PCR
mastermix contained 5 pmol of each primer. 
The final 25 µl volume of the 2nd round reaction mix for
Chlamydia spp contained 10 pmol and 25 pmol of the in-
ner primers CHL2C and CHL2D respectively, 10 mM
Tris-HCl pH 9.0, 3.5 mM MgCl2, 50 mM KCl, 0.2 mM for
each dNTP, 0.1% Triton X-100 and 0.625 units of Taq
enzyme. 
Extracted specimens (5 µl) were added to 20 µl of the
first round mix and subjected to the 1st round cyclingBMC Infectious Diseases 2001, 1:12 http://www.biomedcentral.com/1471-2334/1/12
conditions. A 0.5 µl volume of the reaction product from
the first round was transferred to 24.5 µl of second round
mix for the 2nd round.
Cycling conditions
Hot-start PCR was carried out in a Perkin Elmer Gene-
Amp 2400 thermal cycler. Cycling conditions are given
in Tables 2,3.
First and second round products were visualised togeth-
er on ethidium bromide-stained 2% agarose gels and
photographed (Polaroid). Specimens were regarded as
positive if an appropriately sized band was present on 1st
and/or 2nd round PCR. C. trachomatis, C. pneumoniae
and NFW controls were included in each round for the
respective PCR.
Assay Sensitivity
Stocks of C. trachomatis and C. pneumoniae of known
TCID50 were used to determine the detection endpoints
for the first and second round of the generic nPCR. The
1st and 2nd round endpoints were 10-4 and 10-7 for C. tra-
chomatis and 10-3 and 10 -6 for C. pneumoniae equating
to 1 and 0.001 TCID50 respectively.
Determination of TCID50 for C. trachomatis and C. pneumoniae
Shell vials were seeded with McCoy cells grown in McCoy
growth medium (MEM Eagles, inactivated fetal calf se-
rum, glutamine, non essential amino acids, gentamicin)
and incubated for 24 hrs at 37°C in a 10% CO2 environ-
ment. Logarithmic dilutions of 500 µl of C. trachomatis
cell culture controls from 10-3 to 10-7 were added to the
shell vials in rows of 4 for each dilution. After centrifuga-
tion at 2000 rpm for 1 hour at room temperature the vi-
als were incubated for 48 hours at 34°C in a 10% CO2
environment. After 48 hours each shell vial was washed
with PBS and fixed in methanol. 150 µl of a 1:5 dilution
of anti-chlamydia direct mmunofluorescence reagent
(Dako) was added to each shell vial and incubated for 1
hour at 37°C . Following a further wash with PBS the vi-
als were examined for elementary bodies under the im-
munofluorescence microscope. C. pneumoniae was
grown in Hep2 cells using the same protocol and growth
medium as described above. Logarithmic dilutions of
500 µl of C. pneumoniae cell culture controls from 10-2
to 10-5 were added to the shell vials in rows of 4 for each
dilution. For both organisms 1 TCID50 was calculated
using the Karber formula.
PCR of specimens
All carotid specimens and white cells were tested using
generic chlamydia nPCR. Aliquots of extracted DNA
from all carotid specimens were spiked with C. trachom-
atis DNA at a weak dilution of 10-6 (0.01 TCID50) and re-
tested using the generic chlamydia nPCR to monitor for
PCR inhibition. PCR for HLADR-B gene was amplified in
all carotid specimens to ensure adequate DNA was ex-
Table 1: Primers for Chlamydia spp. (CHL2A-2D) and HLADRB gene (Amp A, Amp B).
Primer Sequence Specificity
CHL2A 5'-GAA AAA ACT CTT RAA RTC GG-3' MOMP gene 180/183 bp
CHL2B 5'-CGN ANG CTW ATR GCR TCR CAC CAA G-3' MOMP gene 180/183 bp
CHL2C 5'-TGC CTG TRG GGA AYC CWK CTG AWC CAA G-3' MOMP gene 94 bp
CHL2D 5'-CAA GTN CNR CAA GGA TCR CAA GGA TC-3' MOMP gene 94 bp
AMPA 5'-CCC CAC AGC ACG TTT CYT G-3' HLADRB gene 274 bp
AMPB 5'-CCG CTG CAC TGT GAA GCT CT-3' 1 HLADRB gene 274 bp
Primers A&B were outer primers and C&D were inner primers.
Table 2: PCR Cycling Conditions: Chlamydia genus specific
Cycle Conditions First Round Second Round
PrePCRdenaturation 94°C – 3 min 94°C – 2 min
Denaturation 94°C – 10 s 94°C – 10 s
Annealing 45°C – 10 s 45°C – 10 s
Extension 72°C – 30 s 72°C – 30 s
Number of Cycles 35 35
Table 3: PCR Cycling Conditions: HLA DRB gene
Cycle Conditions First Round
PrePCRdenaturation 96°C – 5 min
Denaturation 96°C – 1 min
Annealing 55 °C – 1 min
Extension 72°C – 1 min
Number of Cycles 40BMC Infectious Diseases 2001, 1:12 http://www.biomedcentral.com/1471-2334/1/12
tracted. Only carotid specimens from which the
HLADRB gene was amplified were included in the study
and tested withchlamydia nPCR.
Serology
The MRL Diagnostics Chlamydia MIF (micro-immun-
ofluorescence) assay [10]was used to detect the presence
of IgG antibodies to antigens from C. pneumoniae
(TW183), C. psittaci (strains 6BC and DD34) and C. tra-
chomatis (sero-types D-K) at a serum dilution of 1/16.
Slides were viewed at a magnification of 400 on a Leitz
fluorescence microscope within 24 hours by two inde-
pendent observers. Results were graded on a rank scale
0, 1+, 2+, 3+ and 4+.
Histology
Carotid specimens fixed in 10% formalin and embedded
in paraffin wax were sectioned and stained with Haema-
toxylin & Eosin. Specimens were graded histologically as
follows on microscopic examination by 2 investigators:
Grade 0 normal artery, Grade 1 intimal thickening,
smooth muscle cell damage, macrophage and foam cell
infiltration, Grade 2 central necrotic area with overlying
fibrosis, cholesterol clefts and Grade 3 dense fibrosis,
calcification, ulceration, neovascularisation or haemor-
rhage [9]
Results
Patients and Specimens
Three of the 44 cases and their paired controls were ex-
cluded when the HLA DRB gene failed to be amplified
from the atheromatous carotid specimens. Patient char-
acteristics are summarized in Table 4.
PCR of specimens
Chlamydia spp. were not detected in any carotid athero-
ma specimens. All the white cell specimens were nega-
tive for Chlamydia spp. Inhibition of the generic nPCR
was not demonstrated in any carotid specimen when
each aliquot was spiked with target C. trachomatis at a
weak dilution of 10-6.
Serology
Twenty-five out of 38 (66%) plasma specimens were pos-
itive for C. pneumoniae IgG. Two patients who had anti-
bodies to C. pneumoniae were also positive for C.
trachomatis IgG and one for C. psittaci IgG.
Histology
Apart from the first three carotid specimens from pa-
tients and four post mortem control specimens, all spec-
imens were fixed in formalin for retrospective
confirmatory histological grading following macroscopic
grading. Of the 41 control specimens that were grade 0
macroscopically, 11/41 (27%) were grade 1 and 2/41 (5%)
were grade 2 on histological examination. Thirty disease
specimens were grade 3 macroscopically of which 26
were also grade 3 and 1 was grade 2 on histology. The
first 3 specimens were not examined histologically. Nine
of 10 specimens of grade 2 on gross examination were
confirmed as grade 2 and 1 as grade 1 on histology. One
specimen was grade 1 on both macroscopic and micro-
scopic examination.
Discussion
The number of specimens analyzed in this study was rel-
atively small therefore the null finding could be due to
chance. Previous meta-analysis showed the occurrence
of C. pneumoniae in atheromatous lesions compared to
non-atheromatous vessels of controls was 59% versus
3.1%[8]. In our study Chlamydia spp. were not detected
in any of the atheromatous carotid specimens which is
the same as detection rates in a study of abdominal aortic
aneurysms carried out by Lindholt et al[11].Weiss et al
only detected C. pneumoniae in one coronary atheroma
[6]. C. pneumoniae was only detected in 4/50 (8%) cor-
onary atherectomies from patients in Germany [7].
Several measures were taken to ensure that our results
were not false negatives. The sensitivity of the nPCR was
determined by comparing the endpoints with titrations
of C. trachomatis and C. pneumoniae of knownTCID50.
The nested approach gave a 103 increase in sensitivity.
This was to ensure that the lack of detection of Chlamy-
dia spp. was not due to lack of sensitivity of the nPCR.
We looked for the presence of inhibitors in the tissue
specimens. An aliquot of each extracted DNA specimen
was spiked with a weak dilution of C. trachomatis DNA
and amplified by PCR to exclude such inhibitors. We did
Table 4: Characteristics of patients with carotid artery disease 
that underwent carotid endarterectomy and were enrolled in the 
study.
Characteristic No.(%) of patients
Men 25 (66)
Women 13 (34)
Hypercholesterolaemia 21 (55)
Hypertension 11 (29)
Diabetes mellitus 1 (3)
Family history of CVA*/MIφ /PVD# 16 (42)
Smoker 6 (16)
Ex-smoker 20 (53)
Previous CVA/MI 19 (50)
*CVA = cerebrovascular accident, φ MI = myocardial infarction, #PVD 
= peripheral vascular diseaseBMC Infectious Diseases 2001, 1:12 http://www.biomedcentral.com/1471-2334/1/12
not demonstrate any inhibition to our assay. In retro-
spect it would have been useful to spike the tissue sample
with whole chlamydia particles prior to extraction to de-
termine whether chlamydia DNA was being lost at the
extraction step. Further studies should look at this as-
pect.
The size of specimens and method of DNA tissue extrac-
tion may account for the differences in the rate of detec-
tion. The heterogeneity of distribution of the organism
within the tissue may elude detection by various meth-
ods as noted by Jackson et al [4]. Jantos et al [7]who used
a different method and Paterson et al [12]who looked at
larger samples of carotid endarterectomy and carotid
and coronary arteries from autopsy also failed to detect
C. pneumoniae . In this study the Qiagen tissue DNA kit,
which is specific for DNA extraction from tissue samples,
was used. The cumulative tissue analyzed in this study
argues against the negative findings resulting from inad-
equate amounts of tissue investigated. In order to ensure
that adequate DNA was extracted in this study, the
HLADRB gene was amplified in each specimen. Results
of chlamydia PCR in each individual specimen were only
considered valid when the HLADRB gene was success-
fully amplified and when inhibition to the PCR was ex-
cluded. Care was also taken at all stages to avoid
contamination of specimens, especially at the stage of
DNA tissue extraction.
The difficulty of obtaining adequate numbers of disease-
free and age and sex matched controls has been a prob-
lem in previous investigations, especially in an elderly
population. Taylor-Robinson suggested the best control
comprises disease-free specimens adjacent to abnormal
areas in vessels from the same subjects [8]. One study
showed that C. pneumoniae was not detected by electron
microscopy in adjacent tissue without disease [5]. In our
study external controls from 8 age and sex matched post
mortem patients were used when we were not able to
identify adjacent tissue free of atheroma on macroscopic
examination in patient specimens. Although 13/41 (32%)
of the controls were found retrospectively on histology to
have signs of early atheroma development, Chlamydia
spp. were not detected. There is much evidence from
many workers that C. pneumoniae is present in athero-
matous material including studies using electronmicros-
copy, antigen detection and even culture.[13] However
sensitive techniques such as PCR should be the gold
standard for detection of organisms at low levels in
atheromatous material. The wide range in detection
rates in the literature is therefore surprising.
Apfalter et al have recently published a multicenter com-
parison trial of DNA extraction methods and PCR assays
for detection of C. pneumoniae in endarterectomy speci-
mens.[14] Despite this study an explanation for the wide
discrepancies is unclear. In the Apfalter et al. study, the
majority of methods (10/16) found all 15 specimens neg-
ative. Hence the majority consensus among the expert
laboratories was that all the specimens were negative.
Three methods were able to detect the low positive con-
trol (0.01 inclusions). Of these 3 most sensitive methods
2/3 found all 15 specimens negative. In contrast, of the 2
laboratories that detected C. pneumoniae in the most
clinical specimens, one does not detect the lowest posi-
tive control. This less sensitive laboratory/method (A)
was the one that had the most positive results (9/15).
Unfortunately the study design employed by Apfalter et
al. was not ideal for assessing specificity as only one neg-
ative control was employed. Suspiciously, the two labo-
ratories that detect the most positives share a common
extraction methodology (Boehringer High Pure PCR
template preparation kit). This is a relatively intricate
method with 6 spin steps. The consequent increase in
manipulation steps over that associated with other ex-
traction methods makes this method inherently poten-
tially prone to amplicon and carry-over contamination.
Working in a routine clinical laboratory, we avoid such
potentially non-robust methods because of the potential
associated specificity problems. The positive control data
(samples C1-4) do not suggest that the Boehringer High
Pure PCR template preparation kit confers a higher sen-
sitivity as 2 methods not using this kit had better sensi-
tivity than method A, and a further 7 labs had equivalent
sensitivity to method A. The two 'best' laboratories yield
9/15 (lab A) and 5/15 (lab B) positive results. The con-
cordance between these two laboratories is not accessi-
ble from the data presented in the paper. We are not told
if the 5/15 positives in lab B are included in the 9/15 pos-
itives in lab A. In addition the positive PCR products
were not sequenced. Thus there was no attempt to show
if the positive products represent real positive samples or
are related to amplicon or carry-over contamination
from laboratory or control samples. PCR contamination
is an insidious problem. PCR contamination remains a
viable explanation for the constellation of results pre-
sented by Apfalter et al. It is possible that the literature
in this area is biased by false positive PCR results.
This work in the current study was carried out in a diag-
nostic laboratory (Regional Virus Laboratory, Belfast).
We routinely use nested PCR assays as diagnostic proce-
dures. In this setting we necessarily place much empha-
sis on specificity, including robust extraction
methodologies and minimization of potential for con-
tamination.
A publication bias against negative findings in well-con-
ducted studies is something to be guarded against as itBMC Infectious Diseases 2001, 1:12 http://www.biomedcentral.com/1471-2334/1/12
compromises future systematic review. We feel that this
may be a particular problem in this subject area. We feel
that there is a particular role for electronic journals such
as BMC in which space, in contrast to paper journals, is
not a limitation. Unlimited publication space will in-
crease the chance that papers with negative findings are
published.
Chlamydia spp. were not detected in carotid atheroma in
this group of patients despite a high prevalence of C.
pneumoniae antibodies comparable to that previously
reported in the Northern Ireland population [15], an area
with a high prevalence of atherosclerotic disease. Weiss
et al who only detected the organism in one coronary
atheroma by PCR also found that seroprevalence for C.
pneumoniae antibodies did not correlate with the pres-
ence of C. pneumoniae in coronary atheroma in the pa-
tients in his study [6]. This implies that if there is any
causal association between C. pneumoniae and athero-
genesis then it must be indirect or that it is a variable that
is not essential for atheroma development.
Conclusion
In this study we were not able to detect the presence of
Chlamydia spp. in atheromatous specimensusing nPCR.
Hence we are not able to support the direct involvement
of chlamydia in the atherogenesis of carotid disease.
Even if C. pneumoniae is present in atheromatous mate-
rial it does not indicate that there is a causal association
of infection with the organism and atherosclerosis. Other
factors such as alteration of lipid profile [16], cytokine
mediated endothelial injury [17,18] molecular mimicry
[19] or immune cross reactivity [20] may be an explana-
tion for an indirect relationship of C. pneumoniae with
atherogenesis considering the high prevalence of C.
pneumoniae antibodies in this population.
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